Fludarabine was nearly discarded from clinical use because of severe neurotoxicity at high doses. 1 It is now a critical component of reduced intensity conditioning (RIC) hematopoietic cell transplantation (HCT) at lower doses. Currently, transplantation literature ascribes most drug-induced neurotoxicity to radiation, BU, CYA and MTX. 1, 2 Beitinjaneh et al. 3 recently described a heterogeneous group of patients with fludarabine-associated leukoencephalopathy (LE). However, all the patients had received CYA, the most common diagnosis was posterior reversible encephalopathy syndrome, and the acute toxic leukoencephlopathy (ATL) subset had imaging features of periventricular LE. 4 In addition, Lee et al. 5 recently described retrogeniculate blindness in adults exposed to fludarabine and radiation (GVHD prophylaxis unkown). We hypothesize that despite the use of a well-established fludarabine dose regimen, and the absence of BU, CYA and MTX in the transplant regimen, fludarabine can be unexpectedly and irreversibly neurotoxic. In all, 2 out of 157 children who received fludarabine-containing RIC HCT in our institution developed fludarabine-induced debilitating visual, corticospinal and sensory pathway-necrotizing LE, and eventually succumbed to sepsis.
The first patient was a previously described 6 14-year-old boy with hypodiploid ALL. He had a history of vincristine neuropathy with induction therapy and had received 18 Gy craniospinal radiation and multiple courses of triple intrathecal chemotherapy for central nervous system (CNS) relapse. A second (BM) relapse occurred on therapy. After achieving a third CR, he was treated with a haploidentical donor HCT (no available HLA-matched donor). His last intrathecal therapy was 33 days prior to transplant. His preparative regimen included fludarabine 40 mg/m 2 per day Â 5 days, thiotepa, melphalan and OKT3, with mycophenolate and T-cell depletion as additional GVHD prophylaxis. 7 OKT3-induced fevers complicated his initial course. Aches, chills and occasional rigors were treated with meperidine. On day þ 10, he developed decreased sensation in bilateral lower extremities with paresthesia, foot drop, patellar hyperreflexia and ankle clonus; spinal magnetic resonance imaging (MRI) was negative. Two days later, he achieved neutrophil engraftment, but had trouble walking. By day þ 15, paresthesia progressed to the level of the xiphoid, but brain and spinal MRI were normal. Reflexes diminished, and he became emotionally labile. His only CSF abnormality was an elevated myelin basic protein (16 mg/L), with negative PCR viral testing (including JC virus). One week later, he remained anxious and dyspneic despite normal oxygenation. Although narcotics were discontinued, he remained disoriented, sleepy and could not see. On day þ 35, an electroencephalogram showed diffuse slowing, and MRI on day þ 35 and þ 54 ( Figure 1 ) showed new and progressive (respectively) retrogeniculate optic radiation (A)-, corticospinal tract (B)-and sensory tract (C)restricted diffusion, consistent with ongoing demyelination. He soon required intubation and mechanical ventilation for progressive autonomic instability. A sural nerve biopsy showed severe axonal degeneration. The next 2 months were marked by no spontaneous movements, some withdrawal to pain, eyes open without focus, progressive MRI changes (day þ 206)-diffuse atrophy, progressive white-matter LE extending to the subcortical U-fibers ( Figure 1 ) and restricted diffusion of the optic nerves, chiasm, mamillary bodies and hypothalamus (not demonstrated). By day þ 100, he had successfully received a tracheostomy and was in a persistent vegetative state. Although his mother occasionally noted communication, he had no documented independent movements. Over the next few months, he was intolerant to enteral feeding, fought intermittent GVHD and infections and eventually succumbed to sepsis 9 months post transplant.
Four years later, a 16-year-old girl received a haploidentical HCT for secondary MDS. Pre-transplant evaluation was remarkable only for decreased creatinine clearance (69 mL/min/1.73 m 2 ), and she received the same fludarabine-containing regimen described above.
Her early peri-transplant course was complicated by fever and rigors, treated with meperidine. On the day of her last fludarabine infusion, she experienced hallucinations, which were considered secondary to fever and meperidine and resolved without intervention. She achieved neutrophil engraftment by day þ 9, leading to resolution of mucositis. By day þ 14, her body aches were nearly resolved, but she developed progressive bilateral foot pain. By day þ 23, her foot pain was unresponsive to narcotics, and she developed pins and needles in her upper chest. She next developed autonomic instability, and could no longer ambulate without assistance. She could only see colors, not shapes, and became confused and tearful. Brain MRIs performed on day þ 27 and again 2 days (Figure 2 ) later showed a diffuse necrotizing LE involving the retrogeniculate optic radiations (A), corticospinal tract (B) and sensory tract (C). She was transferred to the intensive care unit for aggressive management of severe total body neuropathic pain. CSF was normal except for elevated myelin basic protein (6.6 mg/L), and PCR (including JC) was again negative. Over the next few weeks, her deterioration continued to the point of no purposeful movement, vocalization and apparent pain. At day þ 51, MRI showed continued progression of the white-matter changes (Figure 2 ). Her parents noted rare moments of cortical function, but true neurological improvement remained absent. By day þ 107, a tracheostomy was placed for intermittent apneic spells, and she was discharged to home on hospice care. She too failed to tolerate significant enteral feeding, even in the absence of GVHD. She developed urosepsis and died 6 months post transplant.
The clinical and radiological features present in our patients are unique among post-HCT neurological complications and are consistent with necropsy descriptions of the diffuse necrotizing LE described in the early fludarabine phase I trials. [8] [9] [10] Our patients developed lower extremity sensory neuropathy a few weeks post HCT, with concomitant MRI changes first documented on days þ 27 and þ 35, respectively. They soon progressed to retrogeniculate blindness, with rapidly progressive total body sensory and motor neuropathies. Late findings included autonomic instability with feeding intolerance. Although there were suggestions of higher cortical function, effective expression and communication were not possible. Our patients remained neurologically devastated until succumbing to infection.
Our report is the first to describe the complete clinical and concomitant distinguishing imaging features on MRI. Distinct from ATL, there was ongoing and progressive restricted diffusion involving specific tracts: bilateral retrogeniculate optic radiations and the entire corticospinal tracts, from the vertex of the brain to the upper spinal cord without associated enhancement. Why some of the oldest myelinated tracts in the CNS have apparently selective vulnerability to fludarabine toxicity is unknown. Whether these patients had identifiable predisposition is also unclear. One patient had an extensive history of CNS insult, which plausibly could predispose to fludarabine-induced severe necrotizing LE. The second patient did not share this Figure 2 . Similarly, the initial MRI showed a diffuse acute demyelinating process involving the retrogeniculate optic radiations (A), corticospinal tracts (B) and sensory tracts (C), which progressively lead to rarefaction of tissue matrix in involved areas with time. Follow-up T2W images at day þ 51 MRI showed continued progression of the white-matter changes.
background however. She did have a modest decrease in creatinine clearance, which may have increased her drug exposure, 11 though its contribution to her toxicity remains purely speculative.
In conclusion, fludarabine-induced severe necrotizing LE has unique clinical, pathological and radiological features that should aid early diagnosis and prognostication for afflicted patients. This rare but lethal drug toxicity may be underrecognized and deserves detailed characterization and analysis of risk factors in a larger cohort of patients.
